专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US08216838B2 Method for efficient production of monocyte-derived multipotent cell (MOMC) 失效
标题翻译：高效生产单核细胞衍生多能细胞（MOMC）的方法
公开(公告)号：US08216838B2
公开(公告)日：2012-07-10
申请号：US12738997
申请日：2008-10-22
申请人： Masataka Kuwana , Takashi Kato , Noriyuki Seta , Hiroshi Miyazaki
发明人： Masataka Kuwana , Takashi Kato , Noriyuki Seta , Hiroshi Miyazaki
IPC分类号： C12N5/08 , C12N5/00
CPC分类号： A61L27/3895 , A61L27/3834 , C07K14/522 , C12N5/0668 , C12N2501/20 , C12N2501/21 , C12N2506/11 , C12N2533/52 , G01N33/5023 , G01N33/5047 , G01N33/5073 , G01N33/6863
摘要： It is to provide a practical method for producing efficiently a large amount of MOMC, which is a multipotent cell which is very suitable for cell transplantation for organ regeneration. It was found that by culturing peripheral blood monocytes in vitro on fibronectin in the presence of SDF-1, MOMC can be produced more efficiently, and the present invention has been completed. Specifically, it is a method for producing MOMC by culturing in vitro peripheral blood monocytes expressing CD14 on fibronectin, wherein the in vitro culture is performed in the presence of SDF-1.
摘要翻译：提供一种高效生产大量MOMC的实用方法，该MOMC是非常适用于器官再生的细胞移植的多能细胞。发现通过在SDF-1的存在下在纤连蛋白上体外培养外周血单核细胞，可以更有效地制备MOMC，本发明已经完成。具体而言，是通过体外培养纤连蛋白表达CD14的外周血单核细胞来制造MOMC的方法，其中在SDF-1存在下进行体外培养。

2. 发明申请

US20100261202A1 METHOD FOR EFFICIENT PRODUCTION OF MONOCYTE-DERIVED MULTIPOTENT CELL (MOMC) 失效
标题翻译：有效生产单核细胞衍生多细胞（MOMC）的方法
公开(公告)号：US20100261202A1
公开(公告)日：2010-10-14
申请号：US12738997
申请日：2008-10-22
申请人： Masataka Kuwana , Takashi Kato , Noriyuki Seta , Hiroshi Miyazaki
发明人： Masataka Kuwana , Takashi Kato , Noriyuki Seta , Hiroshi Miyazaki
IPC分类号： G01N33/53 , C12N5/0786 , C07K14/435
CPC分类号： A61L27/3895 , A61L27/3834 , C07K14/522 , C12N5/0668 , C12N2501/20 , C12N2501/21 , C12N2506/11 , C12N2533/52 , G01N33/5023 , G01N33/5047 , G01N33/5073 , G01N33/6863
摘要： It is to provide a practical method for producing efficiently a large amount of MOMC, which is a multipotent cell which is very suitable for cell transplantation for organ regeneration. It was found that by culturing peripheral blood monocytes in vitro on fibronectin in the presence of SDF-1, MOMC can be produced more efficiently, and the present invention has been completed. Specifically, it is a method for producing MOMC by culturing in vitro peripheral blood monocytes expressing CD14 on fibronectin, wherein the in vitro culture is performed in the presence of SDF-1.
摘要翻译：提供一种高效生产大量MOMC的实用方法，该MOMC是非常适用于器官再生的细胞移植的多能细胞。发现通过在SDF-1的存在下在纤连蛋白上体外培养外周血单核细胞，可以更有效地制备MOMC，本发明已经完成。具体而言，是通过体外培养纤连蛋白表达CD14的外周血单核细胞来制造MOMC的方法，其中在SDF-1存在下进行体外培养。

3. 发明授权

US07262062B2 Diagnostic for scleroderma 有权
标题翻译：诊断为硬皮病
公开(公告)号：US07262062B2
公开(公告)日：2007-08-28
申请号：US10877683
申请日：2004-06-25
申请人： Masataka Kuwana
发明人： Masataka Kuwana
IPC分类号： G01N33/564 , G01N33/53 , C07K14/435 , C07K16/18 , C07K16/42
CPC分类号： C07K16/40 , C07K2317/21 , G01N33/686 , G01N33/6881 , G01N2333/9125
摘要： As anti-RNA polymerase (RNAP) antibodies are detected with high frequency in patients suffering from cutaneous scleroderma where skin sclerosis progresses rapidly, supervenes scleroderma renal crisis at a high rate, and associates with clinical entities whose prognoses are extremely bad, it is intended to provide a convenient method of detecting an anti-RNAP antibodies, which is extremely useful in diagnosing and classifying clinical entities of scleroderma, and predicting organ failure, in particular scleroderma renal crisis. In order to identify an epitope recognized commonly by anti-RNAP antibodies, the full length of RPC62 and a partial fragment of RPC155, that are 2 subunits of 62-kDa and 155-kDa of RNAP III, are expressed in Escherichia coli as recombinant proteins, and the reactivities to sera positive and negative to anti-RNAP antibody from patients suffering from scleroderma are examined by immunoblotting method to confirm that an epitope recognized by anti-RNAP antibodies in the sera from the patients suffering from scleroderma exists in 891 to 1020 amino acid residues of RPC155.
摘要翻译：由于皮肤硬化症进展迅速的皮肤硬皮病患者高反应性检测到抗RNA聚合酶（RNAP）抗体，因此以高速率超过硬皮病肾脏危象，并与预后极差的临床实体相关联，提供了一种方便的检测抗RNAP抗体的方法，该方法在诊断和分类硬皮病临床实体以及预防器官衰竭方面非常有用，特别是硬皮病肾脏危象。为了鉴定抗-RNAP抗体通常识别的表位，RPC62的全长和RPC155的部分片段，其是62-kDa和155-kDa的RNAP III的2个亚基，在大肠杆菌中表达为重组蛋白，并通过免疫印迹法检测来自硬皮病患者对抗RNAP抗体的阳性和阴性对血清的反应性，以确认来自硬皮病患者血清中抗-RNAP抗体识别的表位存在于891至1020个氨基 RPC155的酸残基。

4. 发明申请

US20110165600A1 DIAGNOSIS METHOD AND DIAGNOSIS KIT FOR DERMATOMYOSITIS 审中-公开
标题翻译：诊断方法和诊断用于真菌病的药盒
公开(公告)号：US20110165600A1
公开(公告)日：2011-07-07
申请号：US13059444
申请日：2009-07-31
申请人： Masataka Kuwana , Shinji Sato , Takashi Fujita
发明人： Masataka Kuwana , Shinji Sato , Takashi Fujita
IPC分类号： G01N33/53 , C12N9/00
CPC分类号： G01N33/5743 , G01N33/6854
摘要： An object of the present invention is to identify an antigen corresponding to anti-CADM-140 antibody, produce a recombinant protein, and establish an assay system by ELISA or the like. The present invention provides a kit for diagnosing dermatomyositis containing an MDA5 protein shown in SEQ ID NO: 4 or a fragment thereof that is recognized by anti-CADM-140 antibody.
摘要翻译：本发明的目的是鉴定与抗CADM-140抗体相对应的抗原，产生重组蛋白，并通过ELISA等建立测定系统。本发明提供了用于诊断含有由抗CADM-140抗体识别的SEQ ID NO：4所示MDA5蛋白或其片段的皮肌炎的试剂盒。

5. 发明授权

US07795018B2 Monocyte-origin multipotent cell MOMC 失效
标题翻译：单核细胞来源的多能细胞MOMC
公开(公告)号：US07795018B2
公开(公告)日：2010-09-14
申请号：US10549707
申请日：2004-03-18
申请人： Masataka Kuwana , Hiroaki Kodama
发明人： Masataka Kuwana , Hiroaki Kodama
IPC分类号： C12N5/077 , C12N5/0786 , C12N5/0789 , C12N5/0793 , G01N33/00 , G01N33/53
CPC分类号： C12N5/0657 , A61K35/12 , A61K2035/124 , C12N5/0619 , C12N5/0623 , C12N5/0647 , C12N5/0662 , C12N5/069 , C12N2501/585 , C12N2506/115
摘要： The present invention is to provide a multipotent cell wherein the sufficient amount necessary can be stably and conveniently supplied with a minimum invasion, that will not cause rejection at the time of cell transplantation, that has a potential to differentiate into various cells such as mesenchymal cells including bone, cartilage, skeletal muscle and fat, endothelial cells, myocardial cells, neurons, mesenchymal cells, myocardial cells, endothelial cells, neurons induced to differentiate from the multipotent cell, and a therapeutic agent/treating method comprising these as active ingredient. Peripheral blood mononuclear cells (PMBC) are cultured on fibronectin-coated plastic plates for 7 to 10 days. The generating cell population with a fibroblast-like morphology is derived from circulating CD14+ monocyte, with a unique phenotype of CD14+CD45+CD34+ type I collagen+. These cells have a potential to differentiate into mesenchymal cells including bone, cartilage, skeletal muscle and fat, endothelial cells, myocardial cells, and neurons under particular culture conditions.
摘要翻译：本发明提供一种多潜能细胞，其中必需的足够量可稳定且方便地以最小的侵入进行，其不会在细胞移植时引起排斥，其可能分化成各种细胞如间充质细胞包括骨，软骨，骨骼肌和脂肪，内皮细胞，心肌细胞，神经元，间充质细胞，心肌细胞，内皮细胞，诱导与多潜能细胞分化的神经元，以及包含它们作为活性成分的治疗剂/治疗方法。将外周血单核细胞（PMBC）在纤连蛋白涂覆的塑料板上培养7至10天。具有成纤维细胞样形态的产生细胞群源自循环CD14 +单核细胞，具有CD14 + CD45 + CD34 + I型胶原+的独特表型。这些细胞具有在特定培养条件下分化成包括骨，软骨，骨骼肌和脂肪，内皮细胞，心肌细胞和神经元在内的间充质细胞的潜力。

6. 发明申请

US20060171928A1 Monocyte-origin multipotent cell momc 失效
标题翻译：单核细胞来源多能细胞
公开(公告)号：US20060171928A1
公开(公告)日：2006-08-03
申请号：US10549707
申请日：2004-03-18
申请人： Masataka Kuwana , Hiroaki Kodama
发明人： Masataka Kuwana , Hiroaki Kodama
IPC分类号： C12N5/08 , A61K35/30
CPC分类号： C12N5/0657 , A61K35/12 , A61K2035/124 , C12N5/0619 , C12N5/0623 , C12N5/0647 , C12N5/0662 , C12N5/069 , C12N2501/585 , C12N2506/115
摘要： The present invention is to provide a multipotent cell wherein the sufficient amount necessary can be stably and conveniently supplied with a minimum invasion, that will not cause rejection at the time of cell transplantation, that has a potential to differentiate into various cells such as mesenchymal cells including bone, cartilage, skeletal muscle and fat, endothelial cells, myocardial cells, neurons, mesenchymal cells, myocardial cells, endothelial cells, neurons induced to differentiate from the multipotent cell, and a therapeutic agent/treating method comprising these as active ingredient. Peripheral blood mononuclear cells (PMBC) are cultured on fibronectin-coated plastic plates for 7 to 10 days. The generating cell population with a fibroblast-like morphology is derived from circulating CD14+ monocyte, with a unique phenotype of CD14+CD45+CD34+ type I collagen+. These cells have a potential to differentiate into mesenchymal cells including bone, cartilage, skeletal muscle and fat, endothelial cells, myocardial cells, and neurons under particular culture conditions.
摘要翻译：本发明提供一种多潜能细胞，其中必需的足够量可稳定且方便地以最小的侵入进行，其不会在细胞移植时引起排斥，其可能分化成各种细胞如间充质细胞包括骨，软骨，骨骼肌和脂肪，内皮细胞，心肌细胞，神经元，间充质细胞，心肌细胞，内皮细胞，诱导与多潜能细胞分化的神经元，以及包含它们作为活性成分的治疗剂/治疗方法。将外周血单核细胞（PMBC）在纤连蛋白涂覆的塑料板上培养7至10天。具有成纤维细胞样形态的产生细胞群源自循环CD14 +单核细胞，具有独特的CD14 + CD45 + CD34 + SUP + + I型胶原蛋白+ 。这些细胞具有在特定培养条件下分化成包括骨，软骨，骨骼肌和脂肪，内皮细胞，心肌细胞和神经元在内的间充质细胞的潜力。

7. 发明申请

US20050042652A1 Diagnostic for scleroderma 有权
标题翻译：诊断为硬皮病
公开(公告)号：US20050042652A1
公开(公告)日：2005-02-24
申请号：US10877683
申请日：2004-06-25
申请人： Masataka Kuwana
发明人： Masataka Kuwana
IPC分类号： G01N33/53 , A61K38/00 , A61K39/395 , A61P17/00 , C07K14/47 , C07K16/40 , C07K16/42 , C12P21/08 , G01N33/68 , C12Q1/68
CPC分类号： C07K16/40 , C07K2317/21 , G01N33/686 , G01N33/6881 , G01N2333/9125
摘要： As anti-RNA polymerase (RNAP) antibodies are detected with high frequency in patients suffering from cutaneous scleroderma where skin sclerosis progresses rapidly, supervenes scleroderma renal crisis at a high rate, and associates with clinical entities whose prognoses are extremely bad, it is intended to provide a convenient method of detecting an anti-RNAP antibodies, which is extremely useful in diagnosing and classifying clinical entities of scleroderma, and predicting organ failure, in particular scleroderma renal crisis. In order to identify an epitope recognized commonly by anti-RNAP antibodies, the full length of RPC62 and a partial fragment of RPC155, that are 2 subunits of 62-kDa and 155-kDa of RNAP III, are expressed in Escherichia coli as recombinant proteins, and the reactivities to sera positive and negative to anti-RNAP antibody from patients suffering from scleroderma are examined by immunoblotting method to confirm that an epitope recognized by anti-RNAP antibodies in the sera from the patients suffering from scleroderma exists in 891 to 1020 amino acid residues of RPC155.
摘要翻译：由于皮肤硬化症进展迅速的皮肤硬皮病患者高反应性检测到抗RNA聚合酶（RNAP）抗体，因此以高速率超过硬皮病肾脏危象，并与预后极差的临床实体相关联，提供了一种方便的检测抗RNAP抗体的方法，该方法在诊断和分类硬皮病临床实体以及预防器官衰竭方面非常有用，特别是硬皮病肾脏危象。为了鉴定抗-RNAP抗体通常识别的表位，RPC62的全长和RPC155的部分片段，其是62-kDa和155-kDa的RNAP III的2个亚基，在大肠杆菌中表达为重组蛋白，并通过免疫印迹法检测来自硬皮病患者对抗RNAP抗体的阳性和阴性对血清的反应性，以确认来自硬皮病患者血清中抗-RNAP抗体识别的表位存在于891至1020个氨基 RPC155的酸残基。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式